Nectar Lifesciences
19.88
+0.42(+2.16%)
Market Cap₹436.40 Cr
PE Ratio30.47
IndustryHealthcare
Company Performance:
1D+2.16%
1M-18.12%
6M-46.96%
1Y-33.64%
5Y-9.64%
View Company Insightsright
Latest news about Nectar Lifesciences
Nectar Lifesciences to Divest Key Businesses for ₹1,290 Crore 5 days ago
Nectar Lifesciences plans to sell its API, Formulations, and Menthol businesses to Ceph Lifesciences for ₹1,290 crore. The deal is expected to complete by September 20, 2025, subject to approvals. Proceeds will be used for debt repayment, new investments, and shareholder rewards. An EGM is scheduled for August 4, 2025, to seek shareholder approval.
Nectar Lifesciences Reports Q4 Revenue Decline and Significant Loss 5 days ago
Nectar Lifesciences Secures 2-Year GMP Certification from Brazil's ANVISA for Key APIs Apr 30, 2025
Nectar Lifesciences' API Facility Faces Critical Observations in Joint European Inspection Mar 10, 2025